Literature DB >> 29315563

Kinetic modeling of [18 F]VAT, a novel radioligand for positron emission tomography imaging vesicular acetylcholine transporter in non-human primate brain.

Hongjun Jin1, Xuyi Yue1, Hui Liu1, Junbin Han1, Hubert Flores2, Yi Su1,2, Stanley M Parsons3, Joel S Perlmutter1,2,4, Zhude Tu1.   

Abstract

Molecular imaging of vesicular acetylcholine transporter (VAChT) in the brain provides an important cholinergic biomarker for the pathophysiology and treatment of dementias including Alzheimer's disease. In this study, kinetics modeling methods were applied and compared for quantifying regional brain uptake of the VAChT-specific positron emission tomography radiotracer, ((-)-(1-(-8-(2-fluoroethoxy)-3-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)piperidin-4-yl)(4-fluorophenyl)-methanone) ([18 F]VAT) in macaques. Total volume distribution (VT ) estimates were compared for one-tissue compartment model (1TCM), two-tissue compartment model (2TCM), Logan graphic analysis (LoganAIF) and multiple linear analysis (MA1) with arterial blood input function using data from three macaques. Using the cerebellum-hemispheres as the reference region with data from seven macaques, three additional models were compared: reference tissue model (RTM), simplified RTM (SRTM), and Logan graphic analysis (LoganREF). Model selection criterion indicated that a) 2TCM and SRTM were the most appropriate kinetics models for [18 F]VAT; and b) SRTM was strongly correlated with 2TCM (Pearson's coefficients r > 0.93, p < 0.05). Test-retest studies demonstrated that [18 F]VAT has good reproducibility and reliability (TRV < 10%, ICC > 0.72). These studies demonstrate [18 F]VAT is a promising VAChT positron emission tomography tracer for quantitative assessment of VAChT levels in the brain of living subjects.
© 2018 International Society for Neurochemistry.

Entities:  

Keywords:  [18F]VAT; binding potential; positron emission tomography; tracer kinetic modeling; vesicular acetylcholine transporter

Mesh:

Substances:

Year:  2018        PMID: 29315563      PMCID: PMC5897141          DOI: 10.1111/jnc.14291

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  48 in total

1.  Development of novel PET probe [¹¹C](R,R)HAPT and its stereoisomer [¹¹C](S,S)HAPT for vesicular acetylcholine transporter imaging: a PET study in conscious monkey.

Authors:  Shingo Nishiyama; Hiroyuki Ohba; Tatsuhiro Kobashi; Yumi Nakamasu; Hidekazu Nakao; Tokutaro Ogata; Takeru Kitashoji; Hideo Tsukada
Journal:  Synapse       Date:  2014-04-12       Impact factor: 2.562

2.  Visualization of the vesicular acetylcholine transporter in cholinergic nerve terminals and its targeting to a specific population of small synaptic vesicles.

Authors:  E Weihe; J H Tao-Cheng; M K Schäfer; J D Erickson; L E Eiden
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

3.  In vivo imaging of human cholinergic nerve terminals with (-)-5-(18)F-fluoroethoxybenzovesamicol: biodistribution, dosimetry, and tracer kinetic analyses.

Authors:  Myria Petrou; Kirk A Frey; Michael R Kilbourn; Peter J H Scott; David M Raffel; Nicolaas I Bohnen; Martijn L T M Müller; Roger L Albin; Robert A Koeppe
Journal:  J Nucl Med       Date:  2014-01-30       Impact factor: 10.057

4.  Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects.

Authors:  J Logan; J S Fowler; N D Volkow; A P Wolf; S L Dewey; D J Schlyer; R R MacGregor; R Hitzemann; B Bendriem; S J Gatley
Journal:  J Cereb Blood Flow Metab       Date:  1990-09       Impact factor: 6.200

5.  PET imaging of cholinergic deficits in rats using [18F]fluoroethoxybenzovesamicol ([18F]FEOBV).

Authors:  Maxime Parent; Marc-Andre Bedard; Antonio Aliaga; Jean-Paul Soucy; Evelyne Landry St-Pierre; Marilyn Cyr; Alexey Kostikov; Esther Schirrmacher; Gassan Massarweh; Pedro Rosa-Neto
Journal:  Neuroimage       Date:  2012-04-25       Impact factor: 6.556

6.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced acute transient dystonia in monkeys associated with low striatal dopamine.

Authors:  S D Tabbal; J W Mink; J A V Antenor; J L Carl; S M Moerlein; J S Perlmutter
Journal:  Neuroscience       Date:  2006-06-12       Impact factor: 3.590

7.  Ex vivo and in vivo evaluation of (2R,3R)-5-[(18)F]-fluoroethoxy- and fluoropropoxy-benzovesamicol, as PET radioligands for the vesicular acetylcholine transporter.

Authors:  Nicolas Giboureau; Patrick Emond; Roger R Fulton; David J Henderson; Sylvie Chalon; Lucette Garreau; Peter Roselt; Stefan Eberl; Sylvie Mavel; Sylvie Bodard; Michael J Fulham; Denis Guilloteau; Michael Kassiou
Journal:  Synapse       Date:  2007-12       Impact factor: 2.562

8.  Synthesis and in vitro and in vivo evaluation of 18F-labeled positron emission tomography (PET) ligands for imaging the vesicular acetylcholine transporter.

Authors:  Zhude Tu; Simon M N Efange; Jinbin Xu; Shihong Li; Lynne A Jones; Stanley M Parsons; Robert H Mach
Journal:  J Med Chem       Date:  2009-03-12       Impact factor: 7.446

9.  Positron emission tomography imaging of (2R,3R)-5-[(18)F]fluoroethoxybenzovesamicol in rat and monkey brain: a radioligand for the vesicular acetylcholine transporter.

Authors:  Michael R Kilbourn; Brian Hockley; Lihsueh Lee; Phillip Sherman; Carole Quesada; Kirk A Frey; Robert A Koeppe
Journal:  Nucl Med Biol       Date:  2009-05-08       Impact factor: 2.408

10.  Concordance between in vivo and postmortem measurements of cholinergic denervation in rats using PET with [18F]FEOBV and choline acetyltransferase immunochemistry.

Authors:  Maxime J Parent; Marilyn Cyr; Antonio Aliaga; Alexey Kostikov; Esther Schirrmacher; Jean-Paul Soucy; Naguib Mechawar; Pedro Rosa-Neto; Marc-Andre Bedard
Journal:  EJNMMI Res       Date:  2013-10-09       Impact factor: 3.138

View more
  7 in total

1.  In Vivo Characterization of Two 18F-Labeled PDE10A PET Radioligands in Nonhuman Primate Brains.

Authors:  Hui Liu; Hongjun Jin; Zonghua Luo; Xuyi Yue; Xiang Zhang; Hubert Flores; Yi Su; Joel S Perlmutter; Zhude Tu
Journal:  ACS Chem Neurosci       Date:  2018-02-19       Impact factor: 4.418

2.  The impact of dopamine D2-like agonist/antagonist on [18F]VAT PET measurement of VAChT in the brain of nonhuman primates.

Authors:  Hui Liu; Zonghua Luo; Jiwei Gu; Yi Su; Hubert Flores; Stanley M Parsons; Yun Zhou; Joel S Perlmutter; Zhude Tu
Journal:  Eur J Pharm Sci       Date:  2019-11-15       Impact factor: 4.384

3.  No Dopamine Agonist Modulation of Brain [18F]FEOBV Binding in Parkinson's Disease.

Authors:  Roger L Albin; Prabesh Kanel; Teus van Laar; Sygrid van der Zee; Stiven Roytman; Robert A Koeppe; Peter J H Scott; Nicolaas I Bohnen
Journal:  Mol Pharm       Date:  2022-03-15       Impact factor: 4.939

4.  In vitro characterization of [3H]VAT in cells, animal and human brain tissues for vesicular acetylcholine transporter.

Authors:  Qianwa Liang; Sumit Joshi; Hui Liu; Yanbo Yu; Haiyang Zhao; Tammie L S Benzinger; Joel S Perlmutter; Zhude Tu
Journal:  Eur J Pharmacol       Date:  2021-10-07       Impact factor: 4.432

Review 5.  Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade.

Authors:  George Crișan; Nastasia Sanda Moldovean-Cioroianu; Diana-Gabriela Timaru; Gabriel Andrieș; Călin Căinap; Vasile Chiș
Journal:  Int J Mol Sci       Date:  2022-04-30       Impact factor: 6.208

6.  Radiosynthesis and evaluation of a fluorine-18 labeled radioligand targeting vesicular acetylcholine transporter.

Authors:  Xuyi Yue; Zonghua Luo; Hui Liu; Kota Kaneshige; Stanley M Parsons; Joel S Perlmutter; Zhude Tu
Journal:  Bioorg Med Chem Lett       Date:  2018-09-24       Impact factor: 2.823

Review 7.  Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development.

Authors:  Stuart P McCluskey; Christophe Plisson; Eugenii A Rabiner; Oliver Howes
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-21       Impact factor: 9.236

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.